Pfizer, migraine
Pfizer Dodges Challenge to Its Board
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...
Zacks.com on MSN6h
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to NotePfizer (PFE) closed the latest trading day at $26.75, indicating a -0.41% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback